A Study of AZD8233 in Participants With Dyslipidemia

Summary

AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate the dose-dependent reduction in LDL-C after SC administration of multiple doses of AZD8233 as well as the associated adverse effects profile. The data generated will be used to guide choice of doses, dosing regimens, and sample sizes, as well as safety and PD monitoring in the further clinical development program.

Timeline

Start

2020-10-28

Primary completion

2021-07-20

Completion

2021-07-20

Outcome

Met primary endpoint

release “ETESIAN Phase 2b study of ION449 (AZD8233) met its primary and secondary endpoints” ionis.com ↗

Publications

• Clewe O, Rekic D, Quartino AL, Carlsson B, Higashimori M, Wernevik L, Hofherr A, Ryden-Bergsten T, Nilsson C, Knochel J. Population pharmacokinetics of a novel PCSK9 antisense oligonucleotide. Br J Clin Pharmacol. 2024 Jun;90(6):1503-1513. doi: 10.1111/bcp.16046. Epub 2024 Mar 19.

Drugs

Indications